Hypertension as a predictive biomarker for efficacy of Bevacizumab treatment in metastatic colorectal cancer: A meta-analysis

Journal of B.U.ON.

Volumn 19, Issue 4, 2014, Pages 917-924

  Chen, Cui ^a   Sun, Peng ^a,b   Ye, Sheng ^a   Weng, Hui Wen ^a   Dai, Qiang Sheng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Bevacizumab; Hypertension; Meta analysis; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HYPERTENSION; META ANALYSIS; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; STUDY DESIGN; TREATMENT RESPONSE; COLORECTAL TUMOR; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; BIOMARKERS; COLORECTAL NEOPLASMS; HUMANS; HYPERTENSION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84921904311     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-8670.
2. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
3. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508.
4. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
5. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-2019.
6. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
7. Baynes RD, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther 2009;16:554-561.
8. Loupakis F, Bria E, Vaccaro V et al. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res 2010;29:58-66.
9. Neagoe PE, Lemieux C, Sirois MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 2005;280:9904-9912.
10. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54:652-658.
11. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008;19:927-934.
12. Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-230.
13. Dewdney A, Cunningham D, Barbachano Y, Chau I. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poorrisk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer 2012;106:1718-1721.
14. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.
15. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21:3337-3351.
16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
17. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
19. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-826.
20. Yamamura K, Ishigure K. [Analysis of hypertension in advanced, recurrent colorectal cancer patients treated with first-line bevacizumab]. Gan To Kagaku Ryoho 2011;38:85-88.
21. Horinouchi Y, Sakurada T, Nakamura T et al. [Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer]. Yakugaku Zasshi 2011;131:1251-1257.
22. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 2011;68:1207-1213.
23. Osterlund P, Soveri LM, Isoniemi H et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011;104:599-604.
24. Hurwitz HI, Douglas PS, Middleton JP et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013;18:273-280.
25. Ryanne WR, Lindenberg PA, Slack R et al. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer 2009;40:101-108.
26. Tahover E, Uziely B, Salah A et al. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 2013;30:327-335.
27. Cai J, Ma H, Huang F et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol 2013;11:306-315.
28. Welch S, Spithoff K, Rumble RB, Maroun J. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010;21:1152-1162.
29. Ince WL, Jubb AM, Holden SN et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005;97:981-989.
30. Jubb AM, Hurwitz HI, Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-227.
31. Narita Y, Taniguchi H, Komori A et al. CAI 9-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. Cancer Chemother Pharmacol 2014;73:409-416.
32. Bruhn MA, Townsend AR, Khoon Lee C et al. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. Int J Cancer 2014;135:731-741.
33. Pentheroudakis G, Kotoula V, Fountzilas E et al. A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). BMC Cancer 2014;14:111-121.
34. Maitland ML, Bkris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102:596-604.
35. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-680.
36. Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol 2004;5:647.
37. Orditura M, De Vita F, Galizia G et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep 2009;21:1023-1028.
38. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
39. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-smallcell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. T Clin Oncol 2010;28:949-954.
40. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-2143.